BioSpace News Archive

This webinar highlights practical strategies to overcome two key challenges in TCR discovery: poor expression and low affinity. Discover how the innovative WuXian Transient™ system enables high-titer CHO production of sTCRs (~100 mg/L) and TCR-TCEs, and how optimized phage-based affinity maturation routinely delivers ~10,000-fold KD improvements. Through real-world case studies, see how these integrated solutions generate high-quality TCR building blocks in a high-throughput manner, streamlining the path to next-gen TCR-TCE therapeutics.

Whether monitoring post-market performance, demonstrating value to payers, or uncovering new opportunities, the Truveta Data can change the trajectory of your device portfolio.

Amanda is an award-winning freelance science journalist and editor covering everything from ecology and the environment to artificial intelligence and the nitty-grittiest cell and molecular biology. You can find her full portfolio and contact information at www.amandaheidt.com, or follow along on Bluesky and LinkedIn.

Four Los Angeles County life sciences projects are receiving funding to support goals that include adding jobs, creating multitenant facilities for graduation-stage companies, financially supporting emerging businesses and attracting large employers to the area.

Novo Nordisk also lowered its full-year profit growth guidance in connection with the restructuring effort. The pharma now anticipates operating profit to grow from 4% to 10%, down from its prior projection of 10% to 16%.

Cullinan Therapeutics and Taiho Oncology’s zipalertinib elicited promising response rates in two mid-stage studies of non-small cell lung cancer patients with typical and uncommon EGFR mutations.

Former CDC director Susan Monarez and former chief medical officer Debra Houry will appear in front of the Senate HELP Committee on Sept. 17.

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech into the future.

As Novo Nordisk cuts 9,000 people from its organization in a restructuring effort, BioSpace looks back on the Danish pharma company’s rise.